Updated:
Carlin Consumer Health
Carlin Consumer Health is a sector-specialist investor focused on branded OTC wellness, supplements, and consumer healthcare assets in the United States.
Carlin Consumer Health
Healthcare private equity firms Hildred Capital Management, LLC (“Hildred”) and Bourne Partners Strategic Capital (“Bourne”), together with The Emerson Group (“Emerson”), have launched Carlin Consumer Health (“Carlin”) to establish a preeminent consumer health business and to acquire leading over-the-counter (“OTC”) brands. Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
United States
Sector focus
Frequently asked questions
What is Carlin Consumer Health's investment strategy?
The firm targets control and growth-equity investments in branded consumer healthcare businesses, including nutraceuticals, functional supplements, and OTC wellness products. Its strategy focuses on companies with existing retail distribution, compliant manufacturing, and expansion potential through omnichannel sales and eventual strategic sale to large CPG or pharmaceutical acquirers.
Does Carlin Consumer Health make minority investments or only control deals?
The stated posture appears to favor control positions and structured growth equity, though the absence of any published track record, fund documentation, or named portfolio companies makes the precise mix of minority and majority stakes unclear. Typically, consumer health specialists in the lower middle market seek control to drive operational improvements and exit positioning.
How does Carlin Consumer Health source its deals?
Without a website, LinkedIn presence, or disclosed intermediary relationships, deal sourcing likely relies on founder networks, industry trade contacts, and specialized investment bankers operating within the consumer healthcare ecosystem. This is common for sub-institutional funds that compete on sector expertise rather than auction-process scale.
Which sectors or product categories does Carlin Consumer Health avoid?
The firm's name and observable focus suggest it avoids regulated pharmaceuticals, prescription drugs, medical devices, biotechnology, and pure-play healthcare services. The mandate is concentrated on non-pharma consumer products that sit at the intersection of retail health and branded CPG.
Who runs Carlin Consumer Health?
No principals, managing partners, or investment team members have been identified through public record, major financial media, or professional networking platforms as of the most recent review. The firm maintains a deliberately low public profile, and any leadership identification would require direct sourcing or proprietary databases.
Is this a family office or an investment firm?
The firm's structure is not publicly disclosed. The name, lack of regulatory filings, and absence of institutional marketing suggest a closely held partnership or a family-affiliated vehicle operating with a dedicated sector mandate, but no evidence currently confirms either characterization.
Does Carlin Consumer Health have any known portfolio companies or exits?
No confirmed portfolio companies or realized exits are identified in the public record. The firm does not publish case studies, website content, or LinkedIn updates disclosing past or present holdings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: